CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer.
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of an investigational drug called CFI-402257
alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer
patients.